EUVIMEDEUVIMED entdecken
Fallbericht

Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy

Giulia Santo, Gianpaolo Di Santo, Bettina Zelger, Irene Virgolini

Nuklearmedizin - NuclearMedicine · 01.06.2024 · 63 (03) · 219-220

DOI: 10.1055/a-2221-3220 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.06.2024. Verfasst von Giulia Santo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Gallium Radioisotopes, Gallium Isotopes, Pancreatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction Prostate-specific membrane antigen (PSMA) is a transmembrane type II glycoprotein with folate hydrolase and neurocarboxypeptidase activity generally expressed by prostate epithelium and upregulated on the surface of prostatic adenocarcinoma (PCa) cells. Based on its exceptionally high level of PSMA expression by tumor cells, PSMA-based imaging as well as PSMA-based radioligand therapy (RLT) regimens have been introduced in the management of PCa patients. However, PSMA expression has also been demonstrated in the neovasculature of different solid tumor tissues. Even if the underlined mechanism is not completely understood, some preclinical data suggested that PSMA might be involved in cancer-related angiogenesis by degrading the extracellular matrix and participating in integrin signal transduction [ 1 ]. In this scenario, positron emission tomography/computed tomography (PET/CT) imaging by using Gallium-68 ( 68 Ga) or Fluoro-18 ( 18 F)-labeled PSMA ligands can play a role also in tumors beyond PCa. Although the growing interest in the diagnostic performance of PSMA ligands in different solid tumors, data remain limited for some subtypes [ 2 ]. Here we report the clinical case of a 68-year-old man under [ 177 Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer (mCRPC) with the incidental detection of a pancreatic adenocarcinoma on the restaging [ 68 Ga]Ga-PSMA-11 PET/CT. Publication History Received: 02 November 2023 Accepted: 27 November 2023 Article published online: 08 January 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyGallium RadioisotopesGallium IsotopesPancreatic NeoplasmsIncidental FindingsAdenocarcinomaLutetiumHumansMaleDipeptidesHeterocyclic Compounds, 1-RingProstatic Neoplasms, Castration-ResistantEdetic AcidRadiopharmaceuticalsAgedOligopeptidesProstate-Specific Antigen

Substanzen

Gallium RadioisotopesGallium Isotopesgallium 68 PSMA-11LutetiumDipeptidesHeterocyclic Compounds, 1-RingEdetic AcidPluvictoRadiopharmaceuticalsOligopeptides

Autor:innen und Institutionen

  • Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
  • Pathology, Medical University of Innsbruck, Innsbruck, Austria.

Zitieren

APA

Santo, G., Di Santo, G., Zelger, B., & Virgolini, I. (2024). Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy. Nuklearmedizin - NuclearMedicine, 63(03), 219-220. https://doi.org/10.1055/a-2221-3220

Vancouver

Santo G, Di Santo G, Zelger B, Virgolini I. Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy. Nuklearmedizin - NuclearMedicine. 2024;63(03):219-220. doi:10.1055/a-2221-3220

BibTeX
@article{Santo2024,
  author = {Santo, Giulia and Di Santo, Gianpaolo and Zelger, Bettina and Virgolini, Irene},
  title = {Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2024},
  volume = {63},
  number = {03},
  pages = {219--220},
  doi = {10.1055/a-2221-3220}
}
Kostenlos starten →